Selecting the right defibrillator in the younger patient: Transvenous, epicardial or subcutaneous?

Nikolay Bogush, Raul Emilio Espinosa, Bryan C. Cannon, Philip L. Wackel, Hideo Okamura, Paul Andrew Friedman, Christopher J. McLeod

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


The advent of the subcutaneous implantable cardioverter-defibrillator (SQ-ICD) provides an alternative to transvenous and epicardial ICD therapy. Particularly germane to the young patient with congenital heart disease or inheritable arrhythmia syndromes, the SQ-ICD may be ideal for those who do not require permanent cardiac pacing. The serious complications associated with transvenous ICD systems are largely driven by the intravascular components of these devices and are avoided by this extravascular technique. Multiple clinical trials have shown that SQ-ICDs are effective in detecting and terminating ventricular arrhythmias, yet nuanced issues must be considered, especially in the context of congenital cardiovascular anomalies. This review aims to contextualize the role of this technology in contrast with traditional ICDs, and provide a logical approach to appropriate device selection.

Original languageEnglish (US)
Pages (from-to)133-138
Number of pages6
JournalInternational Journal of Cardiology
StatePublished - Jan 1 2018


  • Congenital heart disease
  • Implantable cardioverter-defibrillator
  • Subcutaneous ICD complications

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Selecting the right defibrillator in the younger patient: Transvenous, epicardial or subcutaneous?'. Together they form a unique fingerprint.

Cite this